Lenvatinib Plus Pembrolizumab versus Doxorubicin for Advanced or Recurrent Endometrial Cancer with Short Treatment-Free Intervals Following First-Line Carboplatin Plus Paclitaxel.
Article in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors.
Shao-Jing WangDepartment of Gynecology and Obstetrics, Taichung Veterans General Hospital, Taichung 40705, Taiwan.ORCID 0000-0001-7654-2699
Hsin-Hua ChenDivision of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung 40705, Taiwan.ORCID 0000-0002-7304-4587
Lou SunDepartment of Gynecology and Obstetrics, Taichung Veterans General Hospital, Taichung 40705, Taiwan.ORCID 0000-0001-5561-7110
Yu-Hsiang ShihDepartment of Gynecology and Obstetrics, Taichung Veterans General Hospital, Taichung 40705, Taiwan.
Ting-Fang LuDepartment of Gynecology and Obstetrics, Taichung Veterans General Hospital, Taichung 40705, Taiwan.
Yen-Fu ChenDepartment of Gynecology and Obstetrics, Taichung Veterans General Hospital, Taichung 40705, Taiwan.
Chun-Ting FanDepartment of Gynecology and Obstetrics, Taichung Veterans General Hospital, Taichung 40705, Taiwan.
Shih-Tien HsuDepartment of Gynecology and Obstetrics, Taichung Veterans General Hospital, Taichung 40705, Taiwan.ORCID 0000-0003-0056-7894
Chin-Ku LiuDepartment of Gynecology and Obstetrics, Taichung Veterans General Hospital, Taichung 40705, Taiwan.
Sheau-Feng HwangDepartment of Gynecology and Obstetrics, Taichung Veterans General Hospital, Taichung 40705, Taiwan.
Chien-Hsing LuDepartment of Gynecology and Obstetrics, Taichung Veterans General Hospital, Taichung 40705, Taiwan.ORCID 0000-0001-7860-4320
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Lenvatinib Plus Pembrolizumab versus Doxorubicin for Advanced or Recurrent Endometrial Cancer with Short Treatment-Free Intervals Following First-Line Carboplatin Plus Paclitaxel. · full record | OpenQuestion